Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone aceponate cream versus Advantan versus vehicle in mild to moderate atopic dermatitis
2024-511390-30-00Phase 3Authorised
- Sponsor
- Dermapharm
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone aceponate in atopic dermatitis (AD) (3 arms), sponsored by Dermapharm. Planned start Jul 2023; status: authorised.
02
Drugs
methylprednisolone aceponate
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-511390-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511390-30-00.